Securian Asset Management Inc. Sells 5,084 Shares of Gilead Sciences, Inc. $GILD

Securian Asset Management Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.8% during the third quarter, HoldingsChannel reports. The institutional investor owned 59,923 shares of the biopharmaceutical company’s stock after selling 5,084 shares during the quarter. Securian Asset Management Inc.’s holdings in Gilead Sciences were worth $6,651,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC increased its position in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new position in Gilead Sciences in the 4th quarter worth approximately $215,000. Integrated Wealth Concepts LLC increased its holdings in shares of Gilead Sciences by 1.4% in the 1st quarter. Integrated Wealth Concepts LLC now owns 27,069 shares of the biopharmaceutical company’s stock worth $3,033,000 after buying an additional 382 shares during the last quarter. Ashton Thomas Private Wealth LLC increased its holdings in shares of Gilead Sciences by 3.5% in the 1st quarter. Ashton Thomas Private Wealth LLC now owns 45,768 shares of the biopharmaceutical company’s stock worth $5,128,000 after buying an additional 1,551 shares during the last quarter. Finally, Fred Alger Management LLC raised its position in shares of Gilead Sciences by 11.5% during the 1st quarter. Fred Alger Management LLC now owns 33,183 shares of the biopharmaceutical company’s stock valued at $3,718,000 after buying an additional 3,424 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the transaction, the insider directly owned 107,193 shares in the company, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 136,257 shares of company stock worth $16,855,192. 0.27% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on GILD shares. TD Cowen upped their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. UBS Group upgraded Gilead Sciences to a “hold” rating in a research report on Thursday, December 4th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. Morgan Stanley upped their target price on Gilead Sciences from $147.00 to $151.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $131.68.

Gilead Sciences Stock Up 2.6%

NASDAQ GILD opened at $121.36 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock has a market capitalization of $150.57 billion, a PE ratio of 18.82, a PEG ratio of 0.63 and a beta of 0.33. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The business’s 50-day moving average is $123.08 and its 200 day moving average is $117.34.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the business posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were issued a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s payout ratio is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.